Vertex Pharmaceuticals
VRTX
1,567 hedge funds and large institutions have $95.2B invested in Vertex Pharmaceuticals in 2024 Q4 according to their latest regulatory filings, with 203 funds opening new positions, 553 increasing their positions, 621 reducing their positions, and 154 closing their positions.
32% more first-time investments, than exits
New positions opened: 203 | Existing positions closed: 154
15% more capital inflows, than outflows
Capital inflows: $8.34B | Capital outflows: $7.28B
11% more call options, than puts
Call options by funds: $780M | Put options by funds: $700M
1% more funds holding
Funds holding: 1,550 → 1,567 (+17)
0.88% more ownership
Funds ownership: 90.93% → 91.81% (+0.88%)
11% less repeat investments, than reductions
Existing positions increased: 553 | Existing positions reduced: 621
45% less funds holding in top 10
Funds holding in top 10: 29 → 16 (-13)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Parnassus Investments
San Francisco,
California
|
+$842M |
| 2 |
Capital World Investors
Los Angeles,
California
|
+$702M |
| 3 |
Capital Research Global Investors
Los Angeles,
California
|
+$661M |
| 4 |
Edgewood Management
Greenwich,
Connecticut
|
+$654M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
+$518M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AllianceBernstein
Nashville,
Tennessee
|
-$1.6B |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$605M |
| 3 |
Jennison Associates
New York
|
-$571M |
| 4 |
Massachusetts Financial Services
Boston,
Massachusetts
|
-$286M |
| 5 |
JP Morgan Chase
New York
|
-$285M |
VRTX Hedge Fund Activity: Q4 2024 in Review
1,567 of the 7,620 institutional investors tracked by Wall St. Rank reported a position in Vertex Pharmaceuticals (VRTX) for Q4 2024, worth a combined $95.2B — down 13% from $109B a quarter earlier.
Buyers outnumbered sellers: 203 funds opened new VRTX positions and 154 closed out — a net gain of 49 holders — while 553 added to existing stakes and 621 trimmed.
The largest buyer was Parnassus Investments, opening a new position worth an estimated $842M. The largest seller was AllianceBernstein, cutting an estimated $1.6B.
- 1,567 institutional investors held Vertex Pharmaceuticals (VRTX) as of Q4 2024, up from 1,550 in Q3 2024.
- Funds reported $95.2B of Vertex Pharmaceuticals stock for Q4 2024, down 13% quarter-over-quarter.
- 203 funds opened new Vertex Pharmaceuticals positions in Q4 2024 and 154 closed out, a net change of +49 holders.
- The largest Vertex Pharmaceuticals buyer in Q4 2024 was Parnassus Investments, an estimated $842M added.
- The largest Vertex Pharmaceuticals seller in Q4 2024 was AllianceBernstein, an estimated $1.6B sold.
Based on aggregated 13F filings for Q4 2024.